Immunome, Inc.
$19.81
-4.7%Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -8.2).
Valuation inputs: P/E -8.2, earnings yield N/A, momentum -4.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -33.5%, ROIC -33.6%).
Profitability stack: net margin -30.6%, ROE -33.5%, ROIC -33.6%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +7.1%, momentum -4.7%, net margin -30.6%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Immunome, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Immunome, Inc. Fair Value Envelope
Immunome, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Immunome, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Immunome, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Immunome, Inc. Street Expectations Map
Wall Street analysts project that IMNM stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 36.33, with estimates ranging from a low of 32.00 to a high of 40.00.
The consensus 1-year price target stands at 36.33, with estimates ranging from a low of 32.00 to a high of 40.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Immunome, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.10M and sold $11.04M worth of IMNM shares, resulting in $8.94M of net selling activity.
3 Months
32.5K
647.77K
138.1K
2.93M
-2.3M
-$2.29M
3-6 Months
68.5K
1.45M
371.9K
8.08M
-6.6M
-$6.62M
6-9 Months
0
0.00
22.0K
29.70K
-30K
-$30K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Siegall Clay B
Director, Officer: President And Ceo
$1.75M
Tsai Philip
Officer: Chief Technical Officer
$205K
Bienaime Jean Jacques
Director
$147K
Top Sellers
Barchas Isaac
Director
$8.08M
Rosett Max
Officer: Chief Financial Officer
$1.39M
Wagenheim Philip
Director
$1.34M
Higgins Jack
Officer: Chief Scientific Officer
$234K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $8.94M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
IMNM has not reported any dividend yield values in the available annual periods.
imnm Dividend History
Learning Layer
Related Guides
Build conviction on IMNM by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.